DKD-C Mission
Working Together to Address the Urgent and Unmet Needs in the Diagnosis and Treatment of People with Diabetic Kidney Disease.
DKD-C Spotlights
New Online Learning Module: Management of Chronic Kidney Disease in People with Diabetes
This new online learning module is intended for healthcare providers who care for individuals with chronic kidney disease and diabetes. This module applies to those practicing in primary care, endocrinology, cardiology, diabetology, and nephrology.
Practitioners who should consider this module include:
- Physicians
- Trainees
- Pharmacists
- Nurses
- Nurse Practitioners
- Physician Assistants
- Dietitians
NOTE: Upon completion of this module and the evaluation, you will have the opportunity to print a Certificate of Attendance. Your input on the evaluation will assist ASN in updating this resource in the future.
Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease
Access to care and implementation of breakthrough therapies for DKD can save millions of lives by preventing kidney failure, cardiovascular events, and premature death. Coalitions comprised of patients, families and community groups, healthcare professionals, healthcare systems, federal agencies and payers are essential to develop collaborative models that successfully address this major public health challenge.
Published: June 1, 2022
Online Learning Modules
ASN has developed these online learning modules in partnership with the Centers for Disease Control and Prevention (CDC). These self-paced online resources focus on key infection prevention techniques and patient safety concepts in a case-based format.
Resource Library Highlights
Implementing New DKD Treatments – Time to Act
The American Society of Nephrology’s (ASN’s) Diabetic Kidney Disease Collaborative (DKD-C) conducted the second in a series of three strategy conferences on April 20, 2021. Conference participants strategized on how nephrologists and primary care physicians can work together to ensure the implementation of new diabetic kidney disease therapies, such as SGLT2 inhibitors.
